Building on these findings, we initiated a Phase Ia trial (NCT02996773) to evaluate the feasibility of using PT-BEN in pediatric and young adult patients with hematologic malignancies undergoing haplo-BMT (23, 27). Here, GTF2IRD1 is linked to hematologic disorder.